Antibiotic Review

Total Page:16

File Type:pdf, Size:1020Kb

Antibiotic Review 8/28/19 Disclosure 2 E. Monee’ Carter-Griffin DNP, MA, RN, ACNP-BC Antibiotic has no financial relationships with commercial Review interests to disclose. Any unlaBeled and/or E. Monee’ Carter-Griffin, DNP, MA, RN, ACNP-BC unapproved uses of drugs or products will Be Associate Chair for Advanced Practice Nursing disclosed. University of Texas at Arlington, College of Nursing & Health Innovation Dallas Pulmonary & Critical Care, PA • Identify the general characteristics of • SusceptiBility à determine which antibiotics. antibiotics a bacteria is sensitive to • Discuss the mechanism of action, • à pharmacokinetics, and spectrum of activity MIC lowest concentration of drug that inhiBits growth of the Bacteria for the most common antiBiotic drug classes. Antibiotic Objectives • Identify commonly prescriBed antiBiotics • Trough à lowest concentration of within the drug classes including dosage Lingo drug in bloodstream range and indication for prescribing. – Collect prior to administration of • Identify special considerations for specific drug antibiotics and/or drug classes. • Peak à highest concentration of • Practice appropriate prescriBing for common drug in bloodstream bacterial infections. • Review Basic antiBiotic stewardship 3 4 principles. • Penicillins • Bactericidal or bacteriostatic • Cephalosporins • Narrow or Broad spectrum • Carbapenems General • Can elicit allergic responses Antibiotic • MonoBactam Characteristics • Affect normal Body flora Drug Classes • Macrolides • Fluoroquinolones • Sulfonamides • Tetracyclines 5 6 1 8/28/19 • Penicillins – Natural penicillins 8 – Aminopenicillins Penicillins Penicillins – Anti-staphylococcal penicillins • Mechanism of action àbactericidal à – Anti-pseudomonal penicillins interrupts cell wall synthesis 7 • Pharmacokinetics • Spectrum of Activity – Gram positive organisms Natural – Penicillin G à mostly given IM, But Natural • Streptococcus species (e.g. S. Penicillins one variation can Be given IV Penicillins pyogenes) • Poorly aBsorBed via PO • Some enterococcus species (e.g. E. faecalis) – Penicillin V à given PO Penicillin G Penicillin G • Staphylococci à only minority; most Penicillin V • Increased gastric acid staBility Penicillin V are resistant • Listeria monocytogenes – Gram negative organisms à limited – AnaeroBes • Bacteroides 9 10 • Fusobacterium species Drug Dosage Route Indication • Special Considerations Natural – Do not administer next to nerve or Penicillin G 1.2 – 2.4 MU IM Most commonly Penicillins artery benzathine used to treat Group A strep (e.g. – ProBenecid decreases renal Penicillin G procaine 2.4 MU x 1 dose IM pharyngitis), and Penicillin G clearance of penicillins. syphilis • Co-administration can be used to Penicillin V Penicillin G 12 – 24 MU daily IV increase concentration levels (parenteral) – Decrease parental dosage when CrCl Penicillin V 125-500 mg every 6- PO is less than 50 ml/min 8h – Allergy 11 12 2 8/28/19 Penicillins: • Pharmacokinetics – Amoxicillin +/- clavulanate à given 13 Beta-lactamase Inhibitors Aminopenicillins PO • StaBle in gastric acid Clavulanic acid (clavulanate) Amoxicillin • Best aBsorBed penicillin SulBactam Amoxicillin/Clavulanate – Ampicillin +/- sulbactam TazoBactam Ampicillin • Ampicillin can Be given PO, IM, or Ampicillin/Sulbactam IV • With the addition of the sulBactam can only Be given IM or IV 14 Penicillins: Drug Dosage Route Indication • Spectrum of Activity – Same activity as natural penicillins Aminopenicillins à susceptible gram-positive Amoxicillin (Amoxil) 250-500 mg every PO Sinusitis, 8h meningitis, organisms 500-875 mg BID susceptiBle UTIs, Amoxicillin – Improved gram-negative coverage Amoxicillin/ 250-500 mg every PO Soft skin infections Clavulanate 8h related to group A • Amoxicillin/Clavulanate Enterobacteriaceae (Augmentin) 875 mg every 12h strep, Otis media, pneumonia Ampicillin • H. pylori à used as part of multi- Ampicillin 250-500 mg every PO, IM, IV drug treatment 6h Ampicillin/Sulbactam • H. influenzae Ampicillin/ 1.5-3 g every 6h IM, IV 15 SulBactam (Unasyn) 16 Penicillins: • Special Considerations • Pharmacokinetics Anti- – Dicloxacillin à given PO – Of note, dosing of drugs with beta- staphylococcal Aminopenicillins lactamase inhibitors is Based on the • Delayed aBsorption when given amoxicillin or ampicillin NOT the Penicillins with meals – Nafcillin à given IM or IV Amoxicillin inhibitor. Dicloxacillin • Poor oral aBsorption Amoxicillin/Clavulanate – Decrease parental dosage when *Methicillin • CrCl is less than 50 ml/min Primarily metaBolized through the Ampicillin Nafcillin liver – MSSA coverage with Amoxicillin/ Ampicillin/Sulbactam Oxacillin – Oxacillin à given IM or IV Clavulanate but none with • Poor oral aBsorption Amoxicillin only 17 • Primarily metaBolized through the 18 – No pseudomonas coverage. liver 3 8/28/19 Anti- • Spectrum of Activity Drug Dosage Route Indication staphylococcal – Drug class also known as the Penicillins Penicillinase-Resistant Penicillins – Gram-positive organisms Dicloxacillin 125-500 mg every PO Drug of choice for 6h MSSA infections à Dicloxacillin • Staphylococcal species cellulitis, Nafcillin 0.5-2 g every 4-6h IV endocarditis, Nafcillin – MSSA* osteomyelitis, and bacteremia Oxacillin • Streptococcal species 0.5 g every 4-6h IM Oxacillin 0.25-2 g every 4-6h IM, IV 19 20 • Anti- • Special Considerations Anti- Pharmacokinetics – Piperacillin +/- tazoBactam à IV staphylococcal – No MRSA coverage pseudomonal Penicillins – Nafcillin tends to Be Better tolerated Penicillins • Piperacillin can also Be given IM – Oxacillin à drug-induced hepatitis • Piperacillin is NOT aBsorBed when Dicloxacillin • Usually reversiBle with discontinuation of Piperacillin given orally. the drug – Ticarcillin +/- clavulanate Nafcillin – Dose adjustments for Nafcillin and Piperacillin/tazobactam potassium à IV only Oxacillin Oxacillin for patients with severe hepatic Ticarcillin and renal dysfunction Ticarcillin/clavulanate potassium 21 22 • Anti- Spectrum of activity Drug Dosage Route Indication – Typically referred to the extended- pseudomonal spectrum penicillins Penicillins – Gram-positive activity Piperacillin (Pipracil) 3-4 g every 4-6h IV, IM Intra-abdominal infections, Piperacillin • Staph. and Strep. pneumonia, severe soft/skin and tissue Piperacillin/tazobactam • NO MRSA coverage. Piperacillin/tazoBactam 3.375-4.5 g every IV (Zosyn) 6-8h infections, sepsis, etc. Ticarcillin – Gram-negative activity Ticarcillin/clavulanate • Including Pseudomonas aeruginosa Ticarcillin +/- clavulanate 0.25-2 g every 4- IV potassium • Also has coverage against potassium (Timentin) 6h EnteroBacteriaceae. 23 24 – AnaeroBic coverage 4 8/28/19 • Special Considerations Anti- • Cephalosporins – Dosage considerations for patients – 1st Generation pseudomonal with renal dysfunction – 2nd Generation Penicillins • Elimination half-life can increase 2- fold in mild to moderate dysfunction – 3rd Generation Piperacillin to 6-fold in severe dysfunction Cephalosporins – 4th Generation – Use caution with Ticarcillin in patients Piperacillin/tazobactam – 5th Generation Ticarcillin with HF due to the high sodium load – High levels of Ticarcillin can increase Ticarcillin/clavulanate seizure risk in patients with seizure potassium disorders 25 26 Penicillins: • Pharmacokinetics st – Cefadroxil, Cephalexin, & 27 1 Generation Cephalosporins Cephradine à PO Cephalosporins • Rapidly aBsorBed from the GI tract • Mechanism of action àbactericidal à • Wide distriBution But do NOT cross interrupts cell wall synthesis Cefadroxil the Blood-brain-barrier Cefazolin – Cefazolin à IM, IV Cephalexin • Widely distriButed as well But poor Cephradine CSF penetration 28 Penicillins: • Spectrum of Activity Drug Dosage Route Indication st – Primarily active against gram- 1 Generation positive cocci. Cephalosporins Cefadroxil (Duricef) 1-2 g/daily in two PO Skin and soft tissue • Staphylococcus divided doses infections, respiratory Cefadroxil • Streptococcus Cefazolin (Ancef) 1-2g every 8h IM, IV infections, some UTIs, and otitis media Cefazolin • NO MRSA coverage. Cephalexin – Minor gram-negative activity Cephalexin (Keflex) 250-1000mg every PO 6-12h • E. coli Cephradine Cephradine (Velosef) 250-500mg every PO • H. influenzae 6-12h • Klebsiella 29 30 5 8/28/19 Penicillins: Penicillins: • Special Considerations • Pharmacokinetics – If cross-sensitivity reaction is to – Cefaclor & Cefprozil à PO 1st Generation 2nd Generation occur with a penicillin, it is most • Rapidly aBsorBed from the GI tract Cephalosporins likely to occur with 1st generation Cephalosporins • Cefaclor slowed aBsorption with cephalosporins. Cefadroxil Cefaclor food. • Cefadroxil • Cefprozil is not affected By food. Cefazolin Cefotetan – Cefazolin can cross the blood-brain- Cephalexin Cefoxitin – Cefotetan & Cefoxitin à IM, IV barrier in severe renal – Cefuroxime à PO, IM, IV Cephradine dysfunction/failure Cefprozil • Rapidly aBsorBed from the GI tract • Encephalopathy Cefuroxime 31 • Increased aBsorption when taken 32 • Seizures with food (PO form) Penicillins: • Spectrum of Activity Drug Dosage Route Indication – Gram-positive coverage 2nd Generation Cefaclor 250-500mg every PO Skin & soft tissue • 8h infections, UTIs, Staphylococcus respiratory tract Cephalosporins Cefotetan 1-2g every 12h IM, IV • Streptococcus infections Cefaclor – Extended gram-negative coverage Cefoxitin 1-2g every 6-8h IM, IV Cefotetan • Same as 1st generation but ADD Cefprozil 250-500mg every PO 12-24h Cefoxitin coverage against Neisseria, Proteus – AnaeroBic coverage Cefuroxime
Recommended publications
  • Cefditoren Pivoxil) Tablets 200 and 400 Mg
    SPECTRACEF® (cefditoren pivoxil) Tablets 200 and 400 mg. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION SPECTRACEF® tablets contain cefditoren pivoxil, a semi-synthetic cephalosporin antibiotic for oral administration. It is a prodrug which is hydrolyzed by esterases during absorption, and the drug is distributed in the circulating blood as active cefditoren. Chemically, cefditoren pivoxil is (-)-(6R,7R)-2,2-dimethylpropionyloxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxy­ iminoacetamido]-3-[(Z)-2-(4-methylthiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate. The empirical formula is C25H28N6O7S3 and the molecular weight is 620.73. The structural formula of cefditoren pivoxil is shown below: cefditoren pivoxil The amorphous form of cefditoren pivoxil developed for clinical use is a light yellow powder. It is freely soluble in dilute hydrochloric acid and soluble at levels equal to 6.06 mg/mL in ethanol and <0.1 mg/mL in water. SPECTRACEF® (cefditoren pivoxil) tablets contain 200 mg or 400 mg of cefditoren as cefditoren pivoxil and the following inactive ingredients: croscarmellose sodium, D-mannitol, hydroxypropyl cellulose, hypromellose, magnesium stearate, sodium caseinate (a milk protein), and sodium tripolyphosphate. The tablet coating contains carnauba wax, hypromellose, polyethylene glycol, and titanium dioxide. Tablets are printed with ink containing D&C Red No. 27, FD&C Blue No. 1, propylene glycol, and shellac. CLINICAL PHARMACOLOGY Pharmacokinetics Absorption Oral Bioavailability Following oral administration, cefditoren pivoxil is absorbed from the gastrointestinal tract and hydrolyzed to cefditoren by esterases.
    [Show full text]
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • Surgical Decolonization and Prophylaxis
    Surgical Decolonization and Prophylaxis SurgicalSurgical Decolonization Decolonization and Prophylaxis and Prophylaxis DECOLONIZATION DECOLONIZATION Nasal Screening Result Recommended Intervention Nasal Screening Result Recommended Intervention MRSA Negative • No decolonization required MSSAMRSA NegativeNegative • No decolonization required MSSA PositiveNegative • Intranasal mupirocin twice daily x 5 days MSSA Positive • Intranasal mupirocin twice daily x 5 days MRSA Positive • Intranasal mupirocin twice daily x 5 days, MRSA Positive AND• Intranasal mupirocin twice daily x 5 days, •ANDChlorhexidine bathing one day prior to surgery ANTIMICROBIAL• ChlorhexidinePROPHYLAXISbathing one day prior to surgery ANTIMICROBIAL PROPHYLAXIS CLINICAL CONSIDERATIONS • Preoperative dose-timing CLINICAL CONSIDERATIONS • PreoperativeWithin 60 minutesdose-timing of surgical incision WithinExceptions: 60 minutes vancomycin of surgicaland fluoroquinolones incision within 120 minutes of surgical incisionExceptions: vancomycin and fluoroquinolones within 120 minutes of surgical • Weightincision-based dosing • WeightCefazolin-based: 2 gm dosingfor patients <120 kg, and 3 gm for patients ≥120 kg Vancomycin:Cefazolin: 2 gm usefor ABW patients <120 kg, and 3 gm for patients ≥120 kg Gentamicin:Vancomycin: use use ABW ABW unless ABW is >120% of their IBW, in which case use AdjBWGentamicin:(see below use ABW for equation)unless ABW is >120% of their IBW, in which case use • DurationAdjBW of(see prophylaxis below for equation) • DurationA single of dose, prophylaxis
    [Show full text]
  • Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and Its Application
    Infect Dis Ther (2017) 6:57–67 DOI 10.1007/s40121-016-0144-8 REVIEW Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application Juwon Yim . Leah M. Molloy . Jason G. Newland Received: November 10, 2016 / Published online: December 30, 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com ABSTRACT infections, CABP caused by penicillin- and ceftriaxone-resistant S. pneumoniae and Ceftaroline is a novel cephalosporin recently resistant Gram-positive infections that fail approved in children for treatment of acute first-line antimicrobial agents. However, bacterial skin and soft tissue infections and limited data are available on tolerability in community-acquired bacterial pneumonia neonates and infants younger than 2 months (CABP) caused by methicillin-resistant of age, and on pharmacokinetic characteristics Staphylococcus aureus, Streptococcus pneumoniae in children with chronic medical conditions and other susceptible bacteria. With a favorable and those with invasive, complicated tolerability profile and efficacy proven in infections. In this review, the microbiological pediatric patients and excellent in vitro profile of ceftaroline, its mechanism of action, activity against resistant Gram-positive and and pharmacokinetic profile will be presented. Gram-negative bacteria, ceftaroline may serve Additionally, clinical evidence for use in as a therapeutic option for polymicrobial pediatric patients and proposed place in therapy is discussed. Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 1F47F0601BB3F2DD. Keywords: Antibiotic resistance; Ceftaroline J. Yim (&) fosamil; Children; Methicillin-resistant St. John Hospital and Medical Center, Detroit, MI, Staphylococcus aureus; Streptococcus pneumoniae USA e-mail: [email protected] L.
    [Show full text]
  • Cefalexin in the WHO Essential Medicines List for Children Reject
    Reviewer No. 1: checklist for application of: Cefalexin In the WHO Essential Medicines List for Children (1) Have all important studies that you are aware of been included? Yes No 9 (2) Is there adequate evidence of efficacy for the proposed use? Yes 9 No (3) Is there evidence of efficacy in diverse settings and/or populations? Yes 9 No (4) Are there adverse effects of concern? Yes 9 No (5) Are there special requirements or training needed for safe/effective use? Yes No 9 (6) Is this product needed to meet the majority health needs of the population? Yes No 9 (7) Is the proposed dosage form registered by a stringent regulatory authority? Yes 9 No (8) What action do you propose for the Committee to take? Reject the application for inclusion of the following presentations of cefalexin: • Tablets/ capsules 250mg • Oral suspensions 125mg/5ml and 125mg/ml (9) Additional comment, if any. In order to identify any additional literature, the following broad and sensitive search was conducted using the PubMed Clinical Query application: (cephalexin OR cefalexin AND - 1 - pediatr*) AND ((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading]) Only one small additional study was identified, which looked at the provision of prophylactic antibiotics in patients presenting to an urban children's hospital with trauma to the distal fingertip, requiring repair.1 In a prospective randomised control trial, 146 patients were enrolled, of which 69 were randomised to the no-antibiotic group, and 66 were randomised to the antibiotic (cefalexin) group.
    [Show full text]
  • UNASYN® (Ampicillin Sodium/Sulbactam Sodium)
    ® UNASYN (ampicillin sodium/sulbactam sodium) To reduce the development of drug-resistant bacteria and maintain the effectiveness of UNASYN® and other antibacterial drugs, UNASYN should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION UNASYN is an injectable antibacterial combination consisting of the semisynthetic antibacterial ampicillin sodium and the beta-lactamase inhibitor sulbactam sodium for intravenous and intramuscular administration. Ampicillin sodium is derived from the penicillin nucleus, 6-aminopenicillanic acid. Chemically, it is monosodium (2S, 5R, 6R)-6-[(R)-2-amino-2-phenylacetamido]-3, 3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate and has a molecular weight of 371.39. Its chemical formula is C16H18N3NaO4S. The structural formula is: COONa O CH 3 N CH O 3 NH S NH 2 1 Reference ID: 4053909 Sulbactam sodium is a derivative of the basic penicillin nucleus. Chemically, sulbactam sodium is sodium penicillinate sulfone; sodium (2S, 5R)-3,3-dimethyl-7-oxo-4-thia- 1-azabicyclo [3.2.0] heptane-2-carboxylate 4,4-dioxide. Its chemical formula is C8H10NNaO5S with a molecular weight of 255.22. The structural formula is: COONa CH 3 O N CH 3 S O O UNASYN, ampicillin sodium/sulbactam sodium parenteral combination, is available as a white to off-white dry powder for reconstitution. UNASYN dry powder is freely soluble in aqueous diluents to yield pale yellow to yellow solutions containing ampicillin sodium and sulbactam sodium equivalent to 250 mg ampicillin per mL and 125 mg sulbactam per mL. The pH of the solutions is between 8.0 and 10.0.
    [Show full text]
  • The Antibacterial Activity of Cefpodoxime and the Novel Β
    Session-198 b SATURDAY-279 The Antibacterial Activity of Cefpodoxime and the Novel -lactamase Inhibitor ETX1317 Against Recent Clinical Isolates of b-lactamase-producing Enterobacteriaceae Entasis Therapeutics S. McLeod1, M. Hackel2, R. Badal2, A. Shapiro1, J. Mueller1, R. Tommasi1, and A. Miller1 1-781-810-0120 1Entasis Therapeutics, Waltham, MA and 2IHMA, International Health Management Associates, Schaumburg, IL USA www.entasistx.com Abstract In vitro activity of ETX1317 vs. comparator BLIs Cumulative activity vs. 911 ESBL-enriched Enterobacteriaceae from 2013-2015 Activity vs. 35 sequenced KPC+ and/or MBL+ Enterobacteriaceae MIC (mg/L) Background β-lactamase inhibition (IC50, µM) Strain ID Species encoded bla genes IPM CAZ-AVI CPD-ETX1317 ETX1317 ETX1317 is a novel, diazabicyclooctenone inhibitor of serine β-lactamases that Number (cumulative %) of isolates inhibited at MIC (mg/L) Class A Class C Class D Drug %S* ARC3528*¥ E. cloacae AmpC [∆308-313(SKVALA)] 0.25 32 0.125 4 restores β-lactam activity against multidrug-resistant Enterobacteriaceae. ETX0282, < 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 > 32 ARC4165*¥ C. freundii CMY-2; AmpC [N366Y]; TEM-1; SHV-5 2 32 ≤0.03 4 the oral prodrug of ETX1317, is currently under investigation in combination with BLI CTX-M-15 SHV-5 KPC-2 TEM-1 AmpC* P99 OXA-24/40 OXA-48 0 5 6 14 19 34 20 27 17 18 18 733 3 CPD 10.8 ARC6479* K. oxytoca NDM-1 16 >32 32 32 cefpodoxime proxetil (CPDP), which is hydrolyzed in vivo to release cefpodoxime 0% 0.5% 1% 3% 5% 9% 11% 14% 16% 18% 20% 100% (CPD).
    [Show full text]
  • Antimicrobial Stewardship Guidance
    Antimicrobial Stewardship Guidance Federal Bureau of Prisons Clinical Practice Guidelines March 2013 Clinical guidelines are made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP) does not warrant these guidelines for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient-specific. Consult the BOP Clinical Practice Guidelines Web page to determine the date of the most recent update to this document: http://www.bop.gov/news/medresources.jsp Federal Bureau of Prisons Antimicrobial Stewardship Guidance Clinical Practice Guidelines March 2013 Table of Contents 1. Purpose ............................................................................................................................................. 3 2. Introduction ...................................................................................................................................... 3 3. Antimicrobial Stewardship in the BOP............................................................................................ 4 4. General Guidance for Diagnosis and Identifying Infection ............................................................. 5 Diagnosis of Specific Infections ........................................................................................................ 6 Upper Respiratory Infections (not otherwise specified) ..............................................................................
    [Show full text]
  • Comparative Study of 5-Day and 10-Day Cefditoren Pivoxil Treatments for Recurrent Group a Β-Hemolytic Streptococcus Pharyngitis in Children
    Hindawi Publishing Corporation International Journal of Pediatrics Volume 2009, Article ID 863608, 5 pages doi:10.1155/2009/863608 Clinical Study Comparative Study of 5-Day and 10-Day Cefditoren Pivoxil Treatments for Recurrent Group A β-Hemolytic Streptococcus pharyngitis in Children Hideaki Kikuta, Mutsuo Shibata, Shuji Nakata, Tatsuru Yamanaka, Hiroshi Sakata, Kouji Akizawa, and Kunihiko Kobayashi Pediatric Clinic, Touei Hospital, N-41, E-16, Higashi-ku, Sapporo 007-0841, Japan Correspondence should be addressed to Hideaki Kikuta, [email protected] Received 20 November 2008; Accepted 23 January 2009 Recommended by Samuel Menahem Efficacy of short-course therapy with cephalosporins for treatment of group A β-hemolytic streptococcus (GABHS) pharyngitis is still controversial. Subjects were 226 children with a history of at least one episode of GABHS pharyngitis. Recurrence within the follow-up period (3 weeks after initiation of therapy) occurred in 7 of the 77 children in the 5-day treatment group and in 1 of the 149 children in the 10-day treatment group; the incidence of recurrence being significantly higher in the 5-day treatment group. Bacteriologic treatment failure (GABHS isolation without overt pharyngitis) at follow-up culture was observed in 7 of the 77 children in the 5-day treatment group and 17 of the 149 children in the 10-day treatment group. There was no statistical difference between the two groups. A 5-day course of oral cephalosporins is not always recommended for treatment of GABHS pharyngitis in children who have repeated episodes of pharyngitis. Copyright © 2009 Hideaki Kikuta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]
  • Below Are the CLSI Breakpoints for Selected Bacteria. Please Use Your Clinical Judgement When Assessing Breakpoints
    Below are the CLSI breakpoints for selected bacteria. Please use your clinical judgement when assessing breakpoints. The lowest number does NOT equal most potent antimicrobial. Contact Antimicrobial Stewardship for drug selection and dosing questions. Table 1: 2014 MIC Interpretive Standards for Enterobacteriaceae (includes E.coli, Klebsiella, Enterobacter, Citrobacter, Serratia and Proteus spp) Antimicrobial Agent MIC Interpretive Criteria (g/mL) Enterobacteriaceae S I R Ampicillin ≤ 8 16 ≥ 32 Ampicillin-sulbactam ≤ 8/4 16/8 ≥ 32/16 Aztreonam ≤ 4 8 ≥ 16 Cefazolin (blood) ≤ 2 4 ≥ 8 Cefazolin** (uncomplicated UTI only) ≤ 16 ≥ 32 Cefepime* ≤ 2 4-8* ≥ 16 Cefotetan ≤ 16 32 ≥ 64 Ceftaroline ≤ 0.5 1 ≥ 2 Ceftazidime ≤ 4 8 ≥ 16 Ceftriaxone ≤ 1 2 ≥ 4 Cefpodoxime ≤ 2 4 ≥ 8 Ciprofloxacin ≤ 1 2 ≥ 4 Ertapenem ≤ 0.5 1 ≥ 2 Fosfomycin ≤ 64 128 ≥256 Gentamicin ≤ 4 8 ≥ 16 Imipenem ≤ 1 2 ≥ 4 Levofloxacin ≤ 2 4 ≥ 8 Meropenem ≤ 1 2 ≥ 4 Piperacillin-tazobactam ≤ 16/4 32/4 – 64/4 ≥ 128/4 Trimethoprim-sulfamethoxazole ≤ 2/38 --- ≥ 4/76 *Susceptibile dose-dependent – see chart below **Cefazolin can predict results for cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime axetil, cephalexin and loracarbef for uncomplicated UTIs due to E.coli, K.pneumoniae, and P.mirabilis. Cefpodoxime, cefinidir, and cefuroxime axetil may be tested individually because some isolated may be susceptible to these agents while testing resistant to cefazolin. Cefepime dosing for Enterobacteriaceae ( E.coli, Klebsiella, Enterobacter, Citrobacter, Serratia & Proteus spp) Susceptible Susceptible –dose-dependent (SDD) Resistant MIC </= 2 4 8 >/= 16 Based on dose of: 1g q12h 1g every 8h or 2g every 8 h Do not give 2g q12 Total dose 2g 3-4g 6g NA Table 2: 2014 MIC Interpretive Standards for Pseudomonas aeruginosa and Acinetobacter spp.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Ceftibuten (hydrate) Item No. 25334 NH2 S CAS Registry No.: 118081-34-8 N Formal Name: (6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-4-carboxy- 1-oxo-2-buten-1-yl]amino]-8-oxo-5-thia-1- O azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, dihydrate • 2H2O Synonym: SCH 39720 H N S MF: C15H14N4O6S2 • 2H2O HO FW: 446.5 H O Purity: ≥98% O N UV/Vis.: λmax: 218, 262 nm Supplied as: A crystalline solid -20°C O Storage: OH Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Ceftibuten (hydrate) is supplied as a crystalline solid. A stock solution may be made by dissolving the ceftibuten (hydrate) in the solvent of choice. Ceftibuten (hydrate) is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of ceftibuten (hydrate) in these solvents is approximately 5 and 2 mg/ml, respectively. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of ceftibuten (hydrate) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of ceftibuten (hydrate) in PBS, pH 7.2, is approximately 0.1 mg/ml. We do not recommend storing the aqueous solution for more than one day.
    [Show full text]